Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Fulcrum Therapeutics, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on developing small molecules for genetically defined rare diseases [1] Company Overview - Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with genetically defined rare diseases, particularly in areas with high unmet medical needs [3] - The company's lead clinical program is pociredir, a small molecule aimed at increasing fetal hemoglobin (HbF) expression for treating sickle cell disease (SCD) [3] - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression, addressing the root causes of gene mis-expression [3] Event Details - The presentation at the J.P. Morgan Healthcare Conference will take place on January 14, 2026, at 10:30 a.m. ET/7:30 a.m. PT [1] - A live webcast of the presentation will be available on Fulcrum Therapeutics' website, with a replay accessible for at least 30 days post-event [2]